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Abstract  
Hägglund, Sara. 2005. Epidemiology, detection and prevention of respiratory virus 
infections in Swedish cattle. With special reference to bovine respiratory syncytial virus. 
Doctor’s dissertation. 
ISSN 1652-6880, ISBN 91-576-6920-1 
 
This thesis deals with the dynamics of bovine respiratory syncytial virus (BRSV), bovine 
parainfluenza virus 3 (PIV-3) and bovine coronavirus (BCoV) infections in Swedish cattle 
herds. It also describes the development of a fluorogenic reverse transcription (fRT)-PCR 
for BRSV diagnosis. Furthermore, BRSV immunostimulating complexes (ISCOMs) and a 
commercial inactivated BRSV vaccine were evaluated in vivo in calves. 
 
By serology, high incidences of PIV-3 and BCoV, and a lower incidence of BRSV, were 
demonstrated in 118 herds in one area of Sweden and at a Swedish bull testing station for 
beef breeds. In the dairy herds, absence of these infections and bovine viral diarrhea virus 
(BVDV) was correlated to absence of respiratory disease, confirming the clinical 
importance of the viruses. There appeared to be a geographical clustering of BRSV and 
BCoV infected herds and infections were as common in herds that did or did not introduce 
new animals, indicating indirect transmission between herds. At the bull testing station, an 
effective spread of virus within the herd was demonstrated. BRSV was involved in a 
disease outbreak, emphasizing the need for effective means to prevent this infection. By 
testing animals prior to admission, the bull testing station was kept free from BVDV during 
a six-year study period. 
 
A single tube BRSV fRT-PCR was shown to be a sensitive, specific and rapid tool to detect 
BRSV in both naturally and experimentally infected animals. The assay required less 
laboratory time, had a lower risk of contamination and allowed higher sample throughput 
than a nested PCR with a comparable sensitivity. Accordingly, the fRT-PCR is suitable for 
BRSV research as well as for routine diagnostic purposes and was used in the vaccine 
evaluation. 
 
The immunogenicity and protection induced by BRSV-ISCOMs were evaluated and 
compared to those induced by a commercial vaccine (CV) in calves. An experimental 
BRSV challenge was used for this purpose. The ISCOMs induced rapid humoral immune 
responses and strong clinical and virological protection despite maternal antibodies in 
calves at vaccination. In contrast, calves vaccinated with the CV and control calves all shed 
virus and developed moderate to severe respiratory disease after challenge. Thus, BRSV-
ISCOMs are promising candidates for future industrial production after further evaluation 
and may also be used to investigate protective immunological parameters against BRSV. 
The CV needs to be further evaluated in controlled field trials. 
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vaccine.  
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Appendix 
Paper I-IV 
The present thesis is based on the following papers, which will be referred to by 
their Roman numerals: 
 
I.  Hägglund, S., Svensson, C., Emanuelson, U., Valarcher, J.F. & Alenius, 
S. 2005. Dynamics of virus infections involved in the bovine respiratory 
disease complex in Swedish dairy herds. The Veterinary Journal.  In 
press. 
 
II.  Hägglund, S., Hjort, M., Öhagen, P., Törnqvist, M. & Alenius, S. A six-
year study on respiratory viral infections in beef calves. Submitted. 
 
III.  Hakhverdyan, M., Hägglund, S., Larsen, L.E. & Belák, S. 2005. 
Evaluation of a single-tube fluorogenic RT-PCR assay for detection of 
bovine respiratory syncytial virus in clinical samples. Journal of 
Virological Methods 123, 195-202. 
 
IV.  Hägglund, S., Hu, K.F., Larsen, L.E., Hakhverdyan, M., Valarcher, J.F., 
Taylor, G., Morein, B., Belák, S. & Alenius, S. 2004. Bovine respiratory 
syncytial virus ISCOMs--protection in the presence of maternal 
antibodies. Vaccine 23, 646-655. 
 
Paper I, III and IV are reproduced by kind permission of the journals concerned.  
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Abbreviations 
ag   antigen 
APC  antigen presenting cells 
BCoV   bovine coronavirus 
BHV-1   bovine herpes virus 1 
bp basepairs 
BRD    bovine respiratory disease 
BRSV   bovine respiratory syncytial virus 
BRV bovine  rotavirus 
BVDV   bovine viral diarrhea virus 
cDNA complementary  DNA 
COD  corrected optical density 
CPE cytopatic  effect 
CV commercial  vaccine 
dNTPs  deoxynucleotide triphosphates  
ELISA  enzyme-linked immunosorbant assay 
F   fusion  
fRT-PCR fluorogenic  RT-PCR 
G   glyco 
HE hemagglutinin 
HN haemagglutinin-neuraminidase 
HRP horseradish  peroxidase 
HRSV  human respiratory syncytial virus 
HRT-18  human rectal tumour cells 
Ig immunoglobulins 
ISCOMs immunostimulating  complexes 
MAbs monoclonal  antibodies 
NSAID  non-steroid inflammatory drug 
ORSV  ovine respiratory syncytial virus 
PCR  polymerase chain reaction 
PFU  plaque forming units 
PI persistently  infected 
PIV-3   bovine parainfluenza virus 3 
ps pig  serum 
RT reverse  transcription 
S spike 
s.c. subcutaneously 
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Introduction 
Respiratory disease in cattle, general background 
Nomenclature  
The bovine respiratory disease (BRD) complex includes several syndromes that 
have been defined according to different epidemiological conditions. Since many 
of the disease-causing pathogens are ubiquitous and adult animals are often 
immune, BRD occurs most frequently in young calves, during the period between 
passive and active immunity. The disease is then called enzootic pneumonia 
(Bryson et al., 1978a; Radostitis et al., 2000). When, in contrast, whole cattle 
populations are naïve to specific infections, BRD epizootics occur that may 
severely affect both calves and adults (Inaba et al., 1972; Elvander, 1996).  
 
The term shipping fever is used when BRD appears after long, stressful transports 
and mixing of animals from different origin, as performed in feedlot rearing. 
Pneumonic pasteurellosis is also often used in these cases although Pasteurella or 
Mannheimia spp. are probably seldom the only aetiological agents (Yates, 1982; 
Storz et al., 2000a). Some forms of interstitial pneumonia, such as ‘fog fever’, 
‘bovine farmer’s lung’, or hypersensitivity reactions against massive Dictyocaulus 
viviparus infections, have previously been classified as atypical interstitial 
pneumonia. However, Radostitis et al. (2000) recommend that the word ‘atypical’ 
be avoided since it might lead to confusion. In a review Yates (1982) stated that 
there is a lack of uniformity in the use of the BRD terminology and no clear 
definitions have been made by scientific commitees. Clinically, the disease often 
appears as pneumoenteritis, since many agents have tropism for epithelial tissue 
both in the respiratory and digestive tract.  
 
Viral and bacterial aetiologies 
Viral infections are detected in most BRD cases that are investigated early after 
the onset of clinical signs (Bryson et al., 1978a). Different viruses are involved, 
such as bovine respiratory syncytial virus (BRSV), bovine herpes virus 1 (BHV-
1), bovine parainfluenza virus 3 (PIV-3), bovine adenoviruses, bovine coronavirus 
(BCoV) and bovine viral diarrhea virus (BVDV) (Stott et al., 1980; Kapil & 
Basaraba, 1997). They sometimes occur in combination and they frequently 
precede bacterial invasion of the lung (e.g. with Mannheimia hemolytica, 
Pasteurella multocida, Haemophilus somnus, Salmonella dublin and 
Arcanobacterium pyogenes) (Babiuk, Lawman & Ohmann, 1988). Bacteria and 
viruses may also interact with Mycoplasma spp. to induce chronic or more severe 
disease in a synergistic manner (e.g. M. bovis, M. dispar, M. bovirhinis and M. 
canis) (Thomas et al., 2002). Bovine rhinovirus and bovine reovirus have low 
pathogenicity as single agens (Stott et al., 1980), whereas the clinical effects of 
bovine influenzavirus and ovine RSV (ORSV) infections in cattle are unclear 
(Graham, Calvert & McLaren, 2002). 
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Predisposing factors 
Several management factors affect the animals’ immune responses against 
respiratory infections, and thus the development of clinical disease: for instance 
low colostrum intake, no previous exposure to the pathogen (by natural infection 
or by vaccination with effective vaccines) and immunosuppressive stress (caused 
by  e.g., poor nutrition, dehydration, low or high temperatures, little rest and 
transportation.) (Virtala et al., 1999). Ammonia and hydrogen sulphide gases from 
manure, as well as dust particles, may additionally serve as irritants and predispose 
for BRD (Callan & Garry, 2002).  
 
The infection dose is also probably important in the clinical outcome of infections, 
because high doses may overcome the host immune responses (Yates, 1982). 
Crowding, large animal groups, poor hygiene, poor ventilation and high humidity 
increase the number of infectious particles in the environment and in aerosols 
(Wathes, Jones & Webster, 1983; Stärk, 1999). Isolation of sick individuals is 
probably an important measure to lower the infection pressure in herds.  
 
A range of factors influence the animals’ risk for exposure to new respiratory 
pathogens, for example: 
i)  direct contact between animals from different sources (e.g. by 
introduction of animals in herds, by mixing of animals from several 
herds, or by contact over fences at pasture). 
ii)  introduction of new pathogens into herds by indirect contact (e.g. by 
vectors or contaminated material). 
iii)  housing of young calves with older animals that may serve as carriers 
or that shed pathogens during transient infections. 
iv)  large animal groups (increases contact between infectious and 
susceptible animals and might favour virulent subpopulations of 
pathogens through passages between many individuals). 
 
Economical impact and incidence 
BRD is economically important. Costs are due to losses of animals, decreased 
weight gains, increased work loads and a considerable consumption of therapeutic 
drugs. Moreover, much is spent on vaccines and prophylactic arrival medication in 
fattening herds, especially in North America. In 1991 the economic impact of 
BRD in the United States was estimated to more than 600 million US dollars 
(Smith, 2000). 
 
European investigators have reported BRD incidences (or BRD treatment rates) of 
22-38% and BRD mortalities of 2-9% in beef herds where animals were observed 
between a few weeks of age to slaughter (Stott et al., 1980; Howard et al., 1987; 
Frankena et al., 1994). Similarly, BRD treatment rates were on average 20% in 30 
Swedish fattening herds during 5-12 weeks of study (19-216 days of age) 
(Bengtsson & Viring, 2000) and BRD incidences were about 7% in Swedish dairy 
calves between birth and three months of age (Svensson et al., 2003; Ortman & 
Svensson, 2004). Svensson et al. (2003) found highest odds ratios for calves 
housed in large-group pens and fed with automatic milk-feeding systems. 
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Cattle rearing in Sweden 
Herd data 
The total number of cattle in Sweden has decreased during recent years and was 
about 1,600,000 heads in 2003 (Swedish Board of Agriculture, 2004). As in other 
parts of Europe (Clausen, 2005), there is a continuous restructuring of the industry 
towards larger and fewer herds. In 2003, the Swedish dairy production was 
concentrated to 9700 holdings (~73% tie stalls and ~27% free stalls) with a mean 
herd size of 41 cows. The housing season lasts from October to May and even 
longer in northern Sweden. Artificial inseminations are performed on about 85% 
of animals and most calvings occur during autumn. The two main dairy breeds are 
Swedish Red and White Breed and Swedish Friesian and the mean annual yield 
was 8073 kg per cow in 2003 (Swedish Dairy Association, 2005a).  
 
In 2003, cows for beef production were dispersed on 13,000 holdings with an 
average herd size of 13 cows. The largest beef breed is Charolais (~6000 cows 
registred in a national beef recording programme), followed by Hereford, 
Simmental, Highland Cattle, Limousin, Aberdeen Angus and Blonde d’Aquitaine 
(Swedish Dairy Association, 2005a). There are additionally about 8500 beef 
rearing enterprises, 200 of which purchase >150 calves/year, generally at 6-10 
weeks of age (M. Törnqvist, Swedish Animal Health Service, personal 
communication). Most beef cattle are slaughtered at a mean carcass weight of 140 
kg (34,000 calves in 2004) or at about 320 kg (241,000 bulls/bullocks in 2004) 
(Swedish Official Statistics, 2005a). 
 
Disease control 
Growth-promoting antibiotics have been banned in Sweden since 1986 (Casewell 
et al., 2003) and antibiotics or vaccines for animal use can only be obtained by 
veterinary prescription. Efforts are made on disease prevention by management 
and most farmers are registered in organisations that are specialised in preventive 
medicine and that provide consultation (Swedish Dairy Association and Swedish 
Animal Health Service). Between 100 and 200 animals are imported and exported 
each year (Swedish Official Statistics, 2005b) and disease surveillance during 
import is carefully regulated by a national organisation, which is supported by 
both the beef and dairy industry (Swedish Farmers’ Disease Control Programme). 
 
As a result of national eradication programmes, Sweden has been declared free 
from BHV-1 since 1998 and from bovine leucosis since 2001. To continually 
monitor these disease free statuses, analyses are performed annually from all dairy 
herds and from a selection of beef herds. A national control programme against 
BVDV is undergoing and in August 2005, 98.5% and 97.2% of the dairy and beef 
herds, respectively, were declared free of this infection (Swedish Dairy 
Association, 2005b). This programme is based on i) serological identification of 
infected and non-infected herds, ii) certification and monitoring of non-infected 
herds and iii) virus clearance of infected herds by removal of persistently infected 
(PI) animals and, most importantly, by protection of non-immune pregnant 
animals from acquiring the infection (Lindberg & Alenius, 1999).  
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Because Sweden is declared free from BHV-1, and most dairy and beef herds are 
free from BVDV, this thesis focuses on three other important viruses in the BRD 
complex: BRSV, PIV-3 and BCoV. Special emphasis is given to BRSV because 
this virus causes severe annual outbreaks of BRD in both young and adult 
Swedish cattle. 
 
Bovine respiratory syncytial virus (BRSV) 
Viral characteristics  
BRSV is an enveloped RNA virus classified as a Pneumovirus in the 
Paramyxoviridae family, order Mononegavirales. Its genomic RNA is single-
stranded, non-segmented, negative sense and is incorporated in helical 
nucleocapsides. The fusion (F) and glyco (G) surface proteins have important 
functions in virus attachment and in cell membrane fusion of host cells. Viral 
polymerases are incorporated in the nucleocapsides and transcription as well as 
replication takes place in the cytoplasm of the cell. Virus assembly and spread 
occur by budding from the cell membrane, by fusion and by lysis of cells 
(Kingsbury, 1990). The major target cells for replication are epithelial cells in the 
respiratory tract and pneumocytes (Viuff et al., 1996; Viuff et al., 2002). 
 
BRSV exists as a single serotype and antibody cross reactivity occurs between 
bovine, human, caprine and ovine RS viruses (Stott & Taylor, 1985). According to 
reactions with panels of monoclonal antibodies (MAbs), BRSV can be divided 
into three antigenic subgroups (A, AB and B) (Furze et al., 1994; Grubbs, Kania 
& Potgieter, 2001) and sequence data reveal six distinct phylogenetic branches 
with isolates from different dates and geographical origin (Valarcher, Schelcher & 
Bourhy, 2000). The average nucleotide homology between BRSV strains is 92% 
and 98% for the G and F protein, respectively (Valarcher, Schelcher & Bourhy, 
2000), as compared with 53% and 89% amino acid identity in G and F between 
human RSV (HRSV) strains of different subtypes (A and B) (McIntosh & 
Chanock, 1990). Bovine and human RSV share 30% and 81% amino acid identity 
in G and F, respectively (McIntosh & Chanock, 1990), and infections have been 
reproduced experimentally with HRSV in cattle (Thomas et al., 1984). BRSV is 
most closely related to the caprine RSV (Trudel et al., 1989), and a high 
seroprevalence to ORSV has been found in cattle, indicating inter-species 
transmission (Grubbs, Kania & Potgieter, 2001). 
 
History 
HRSV was initially isolated from a laboratory chimpanzee (Blount, Morris & 
Savage, 1956) and shortly thereafter from children with respiratory disease 
(Chanock, Roizman & Myers, 1957). After its discovery, this virus became rapidly 
recognised as a major cause of common cold, croup, bronchiolitis and pneumonia 
(Chanock  et al., 1961). In 1968, Doggett and co-workers found antibodies to 
HRSV in bovine sera (Doggett, Taylor-Robinson & Gallop, 1968) and in 1970, 
Paccaud and Jacquier isolated a distinct species of RSV from respiratory samples 
from cattle (Paccaud & Jacquier, 1970). Since then, the importance of BRSV in 
enzootic pneumonia of calves and as a cause of outbreaks of respiratory disease  
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also in adult cattle has been clearly established (Stott & Taylor, 1985; Wellemans, 
1990; Van der Poel et al., 1994; Elvander, 1996; Larsen, 2000).  
 
Clinical signs 
Infections with BRSV are often subclinical, but may cause clinical signs ranging 
between transient fever and dyspnoea (Van der Poel et al., 1993; Larsen, 2000). In 
a study by Verhoeff and van Nieuwstadt (1984) 13 groups of 1- to 15- month-old 
calves with serologically confirmed BRSV infection were investigated for clinical 
signs of disease. Animals in three of these groups showed only mild clinical signs 
of BRD (increased coughing and nasal discharge), whereas 47% of animals in ten 
groups showed abdominal respiration, 50% abnormal breathing sounds on 
auscultation, 59% cough and 62% nasal discharge (Verhoeff & van Nieuwstadt, 
1984a). Occasionally, BRSV infections lead to grave dyspnoea and sometimes 
also subcutaneous emphysema. In these severe cases, the destruction of lung 
parenchyma may lead to anoxia, which is clinically observed as cyanosis followed 
by death (Wellemans, 1990).  
 
Secondary opportunistic bacterial or mycoplasma infections frequently aggravate 
the disease (Bryson et al., 1978b) and although BRSV is sometimes detected as 
the only agent in fatal disease, necropsy in later stages often reveal bacterial 
infections when BRSV is no longer detectable (Verhoeff & van Nieuwstadt, 
1984a; Larsen et al., 1999). This illustrates the importance of early diagnosis in 
BRSV outbreaks. 
 
In contrast to HRSV, which may cause disease during repeated infections (Hall, 
2001), BRSV seems primarily to affect naive animals. Although virus shedding 
occasionally has been detected upon experimental BRSV re-infection, clinical 
disease is seldom observed (Kimman et al., 1987; Tjornehoj, 2000; Taylor et al., 
2005). In agreement with this, i) natural disease is most often seen in calves 
younger than six months in areas where the infection is endemic, probably because 
older animals are immune (Van der Poel et al., 1993) and ii) in areas where BRSV 
is not endemic and where adult cattle remain seronegative to BRSV, severe 
disease may be observed in animals of all ages when the infections are introduced 
(Elvander, 1996).  
 
Maternally derived antibodies, which are predominantly of the IgG1-isotype 
(Uttenthal et al., 2000), provide at least partial protection against clinical signs 
after natural and experimental BRSV infection (Kimman et al., 1987, 1988; 
Belknap et al., 1991). Thus, young animals are also often spared from severe 
disease in outbreaks in areas where BRSV is endemic (Wellemans, 1990).  
 
Epidemiology  
BRSV appears to be spread throughout the world  (Inaba et al., 1972; Baker, 
Ames & Markham, 1986; Motha & Hansen, 1998; Almeida et al., 2005). Studies 
on bulk tank milk showed that 41-89% of herds were antibody positive in 1990 in 
Sweden (n=2237) (Elvander, 1996) and 100% of herds were antibody positive in 
1996 in UK (n=341) (Paton et al., 1998). 
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Clinical disease caused by BRSV is mainly diagnosed in autumn and winter in 
temperate climate zones (Stott et al., 1980). It is unclear which factors favour 
disease during these periods and whether the viruses continue to circulate between 
animals and herds also when they are not frequently detected. It has been proposed 
that BRSV stays latent in animals during summer and is re-activated the following 
winter season, but this has been difficult to prove. In a longitudinal survey, 
including six closed dairy herds with annual BRSV infections in winter, primary 
serological responses were only detected in one herd in summer (June-August), 
indicating that the virus circulates at low levels or not at all during summer (Van 
der Poel et al., 1993). Antibody titre-rises in seropositive cattle were recorded 
during summer in five of six herds, but were not associated with virus 
transmission to sentinel animals. These serological responses were interpreted as 
activation of latent infections that did not lead to virus shedding at levels high 
enough for successful transmission. Provided that the virus was not re-introduced 
by indirect contact, BRSV persisted within these herds and was possibly latent in 
seropositive cattle between high incidence winter seasons. 
 
Attempts to reactivate virus have been made in animals previously infected with 
BRSV. Despite corticosteroid treatment, stress and BVDV or BHV-1 co-
infections, BRSV re-excretion has not been detected, by either virus isolation, 
reverse transcription (RT)-PCR or by sentinels. BRSV specific antibody titre rises 
after provocation have nevertheless been interpreted as an indication of virus 
latency and reactivation (Van der Poel et al., 1993, 1997). Viral messenger RNA 
has also been detected by RT-PCR in lymphnodes of animals 71 days after BRSV 
infection (Valarcher et al., 2001) and, given that the virus persists on farms, 
individual latency rather than continuous circulation between animals is supported 
by mathematic modelling (De Jong et al., 1996). Sequence data from recurrent 
outbreaks in the same herds in different years have revealed considerable 
nucleotide variation, implying that new viral strains are introduced or that latent 
strains evolve dramatically (Larsen, Tjornehoj & Viuff, 2000). Consensus 
sequences of BRSV strains obtained in a herd during one outbreak are identical, 
even if obtained 2-3 weeks apart (Larsen et al., 1998; Larsen, Tjornehoj & Viuff, 
2000; Valarcher, Schelcher & Bourhy, 2000). 
 
Humoral immune responses   
Detection of immunoglobulins (Ig) in body fluids is a specific measure of previous 
infection (or passive immunisation) and isotype kinetics in non-immunised 
animals may be used to estimate the infection date. The kinetics varies according 
to the sensitivity of the assay used for detection and is described below for virus-
specific antibody detection by enzyme-linked immunosorbant assays (ELISAs).  
 
Antibody responses to primary and secondary infections of colostrum-deprived, 
seronegative animals 
Naïve, colostrum-deprived calves show IgM and IgA serum responses from day 8-
14 after experimental BRSV infection, in titres that remain detectable during 12-
29 days (Kimman et al., 1987). Serum IgG1 becomes apparent from day 13-17 
(Kimman et al., 1987; Schrijver et al., 1996) and is detectable for more than 30 
days (Uttenthal et al., 2000). IgG2 is detectable from day 30-90 (Kimman et al.,  
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1987) and probably lasts at least eight months (Larsen, 2000). In lung, nasal and 
eye secretions, IgA stays detectable during several months.  
 
No serum IgM, but rapid secondary serum IgA responses (from day 6-8) and 
increase in serum IgG1 and IgG2 are observed after BRSV re-infection of 
colostrum-deprived calves (four months after primary infection). Strong, rapid 
secondary IgA responses (from day 4-11) and IgM resembling primary responses 
are detected in the respiratory tract (Kimman et al., 1987).  
 
Antibody responses to primary and secondary infections of colostrum-fed, 
seropositive animals 
During primary BRSV infections in presence of maternally derived serum IgG1 
(titres of 1280-2560, 3-week-old calves), both mucosal and serum IgG1, IgG2 and 
IgA responses are completely suppressed (Kimman et al., 1987). A weak serum 
IgM response is sometimes observed and the grade of inhibition tends to be related 
to the level of passively derived serum IgG1 pre-inoculation (Kimman et al., 1987; 
Uttenthal et al., 2000). Nevertheless, after re-infection at a low IgG1 titre (80), 
these animals show rapid serum IgA, IgG1 and IgG2 rises (from day 6-8) and IgA 
in the respiratory tract, indicating that an immunological memory is induced 
during the primary infection. 
 
Experimental models 
Experimental BRSV infections have in most cases resulted in no or very mild 
clinical signs of disease and many vaccines have therefore been evaluated mainly 
for reduction of virus shedding after infection (Belknap, Ciszewski & Baker, 
1995; Larsen, 2000). Different strategies have been applied, such as for route, 
mode and frequency of inoculation, type of inoculum and type of animals. In most 
experiments, the usage of colostrum-deprived calves or calves given BRSV-
specific antibody-negative colostrum has been necessary for reproduction of some 
clinical disease. It is difficult to extrapolate results from such studies to a natural 
situation, where market-purchased young calves, some of which have maternal 
antibodies, are likely candidates for vaccination and where the infection 
sometimes causes severe clinical signs. Recently, however, with the aerosol 
inoculation technique and with a virulent low passage Danish isolate, even 
conventional colostrum-fed calves were severely affected after experimental 
infection (Tjornehoj et al., 2003). This has opened up new possibilities for vaccine 
evaluation in this important animal group. 
 
Bovine parainfluenza virus 3 (PIV-3) 
Viral characteristics 
PIV-3 is an enveloped, negative sense, non-segmented, single-stranded RNA virus 
that belongs to the genus Respirovirus in the Paramyxoviridae family. Its major 
site of replication is epithelial cells in the respiratory tract (Tsai & Thomson, 
1975), but viremia may occur with replication in monocytes (Adair et al., 2000). 
The surface haemagglutinin-neuraminidase (HN) protein and fusion (F) protein 
are important for mucus penetration, attachment and fusion with the host cell  
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membranes. PIV-3 replicates in the cytoplasm of cells and transcription of its 
RNA is made by a viral transcriptase. Virus assembly occurs through budding 
from the host cell membrane and infected cells sometimes form syncytia or lyse 
(Kingsbury, 1990). Variation in strains can be detected by MAbs and sequence 
analysis, but only one serotype occurs in cattle (Bryson, 1990). 
 
Bovine PIV-3 is closely related to ovine and human PIV type 3, which causes 
respiratory disease in lambs and children. There is 77 and 80% amino acid 
homology in the HN and F proteins, respectively, between bovine and human 
strains (Chanock & McIntosh, 1990). Although not regarded as a zoonosis, 
infections have been reproduced experimentally with bovine PIV-3 in primates 
(Pennathur et al., 2003) and one report exists about natural infection with the 
bovine virus in man (Ben-Ishai et al., 1980). Cross-infection between sheep and 
cattle has also been reproduced experimentally (Woods, Sibinovic & Marquis, 
1965). 
 
Clinical signs 
PIV-3 infections cause less serious disease than BRSV (Verhoeff & van 
Nieuwstadt, 1984a), but are nevertheless significantly correlated with BRD (Stott 
et al., 1980). Mild clinical signs such as slight fever, coughing and nasal discharge 
are observed after pure PIV-3 infections in young animals (Bryson et al., 1978a., 
1979; Verhoeff & van Nieuwstadt, 1984a). When animal groups are of uniform 
age (and have uniform susceptibility), many or all individuals in young groups are 
simultaneously affected, whereas older animals generally are immune and do not 
show clinical signs of disease (Verhoeff & van Nieuwstadt, 1984a).  
 
The virus is thought to have a predisposing role in shipping fever and enzootic 
pneumonia; it may be isolated from severe or fatal BRD cases together with 
bacteria and Mycoplasma spp. (Bryson et al., 1978b; Storz et al., 2000a). The 
BRD predisposing function of PIV-3 is probably correlated to its 
immunosuppressive effects on leucocytes (e.g. decreased phagocytosis by alveolar 
macrophages and decreased lymphocyte proliferation) and destruction of the 
mucociliary system (Hesse & Toth, 1983; Babiuk, Lawman & Ohmann, 1988; 
Basaraba et al., 1994; Adair et al., 2000). A decrease in surfactant production by 
alveolar type II cells and impairment of the basement membrane of epithelial cells 
in bronchioli have also been suggested (Tsai & Thomson, 1975). 
 
Epidemiology 
Bovine PIV-3 was first isolated in the 1950s from cattle with clinical signs of 
BRD in the USA (Reisinger, Heddleston & Manthei, 1959). It has subsequently 
been found to have a worldwide distribution with high serum antibody prevalences 
in adult animals (Bryson, 1990). PIV-3 was diagnosed in 11 of 47 and 15 of 17 
BRD outbreaks in Northern Ireland in 1978 and 1998, respectively (Bryson et al., 
1978a; Graham et al., 1999), and PIV-3 infections occurred in replacement 
animals in 19 of 19 Dutch dairy herds during the summer and autumn of 1979 
(Verhoeff & van Nieuwstadt, 1984a).  
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Humoral immune responses 
PIV-3 specific serum IgG is detected about day 8-9 and IgA about day 12 after 
experimental PIV-3 infection. Serum IgM can be detected from day 7 and is also 
detectable after experimental re-infections with short intervals (Graham et al., 
1999). A four-fold increase in serum IgG or a long-lasting IgG antibody titre is not 
always seen after infection in calves with maternal antibodies and this 
phenomenon impairs the serological diagnosis of PIV-3, as for BRSV (Bryson et 
al., 1978a; Graham et al., 1999). 
 
Bovine coronavirus (BCoV) 
Viral characteristics  
BCoV is a group II member of the Coronavirus genus in the Coronaviridae family, 
order Nidovirales. Its virions are enveloped, containing non-segmented, positive-
sense, single-stranded RNA genomes incorporated in helical nucleocapsides. The 
spike (S) and hemagglutinin (HE) surface proteins are important for attachment 
and entry into cells and the genomic RNA is directly translated into an RNA 
polymerase. This then synthesises a full genome-length negative-sense strand, 
from which sets of mRNA are transcribed with different length and a common 
3’end. Replication occurs in the cytoplasm of the cell and assembly occurs by 
budding at the membranes of the endoplasmatic reticulum and the Golgi 
apparatus. Virus is released by secretory mechanisms of the cell, by cell-to-cell 
fusion and by lysis of cells (Clark, 1993). The primary site of replication is 
epithelial cells in the distal small intestine, in colon and in the respiratory tract 
(Reynolds et al., 1985; Saif et al., 1986).  
 
Clinical signs 
BCoV has been associated with calf diarrhea since the early 1970s (Stair et al., 
1972) and is now also generally accepted as a major causative agent of winter 
dysentery in adult cows (Saif, 1990). Infections in both calves and adults implicate 
to varying degrees respiratory clinical signs in addition to diarrhea (Alenius et al., 
1991; Tråvén et al., 2001). The faeces, and sometimes also the respiratory 
secretions (unpublished observations) may contain blood (Espinasse, Savey & 
Viso, 1990; Kapil & Basaraba, 1997).  
 
BCoV is involved in shipping fever and has been significantly associated with 
BRD (Storz et al., 1996; Kapil & Basaraba, 1997; Storz et al., 2000a; Plummer et 
al., 2004). Fatal respiratory disease with large amounts of virus in lungs have been 
reported from calves in feedlots (Storz et al., 2000b). Although most BCoV 
isolates produce only enteric or combined enteric and respiratory signs when 
inoculated experimentally (Reynolds et al., 1985; Kapil et al., 1991), it has been 
suggested that BCoV strains vary in tissue tropism (Lin et al., 2000). However, 
results from animal experiments with strains obtained from animals with 
respiratory or enteric clinical signs do not consistently support this theory (Cho et 
al., 2001). Host factors, such as age, production state or diet, may contribute to the 
fact that respiratory disease is more pronounced in certain animals. The same  
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strain may cause disease in both seronegative calves and adults (Tråvén et al., 
2001) and cows are probably immune to the virus in herds with problems only in 
young individuals (Tråvén, 2000).  
 
Epidemiology 
BCoV is widespread in many countries with high seroprevalences in adult cattle 
(Paton et al., 1998; Tråvén, Bjornerot & Larsson, 1999; Hasoksuz et al., 2005; 
Jeong et al., 2005). Winter dysentery is mainly seen during the winter in temperate 
climate zones and the virus has been suggested to persist between seasons in 
healthy carrier animals (Crouch et al., 1985; Collins et al., 1987). However, the 
diagnostic assays in these studies have been questioned and the results need to be 
confirmed (Saif, 1990). Supporting the theory about latent infections, BCoV 
inoculated experimentally has been detected in intestinal crypts for 21 days (Kapil, 
Trent & Goyal, 1990). In other experiments, shedding was terminated by the latest 
19 days after experimental infections (as determined by PCR) suggesting that the 
infection is self limiting (Cho et al., 2001).  
 
Humoral immune responses 
BCoV-specific serum and milk IgG is detectable from day 9-11 after experimental 
BCoV infection of seronegative animals (Tråvén et al., 2001) and remain so at 
least one year after natural infections without reinfections (Alenius et al., 1991). 
BCoV-specific IgM increases from day 2-7 and remains detectable during 3-6 
weeks, whereas IgA can be detected from day 7-9 and during several months, as 
determined by isotype capture ELISAs (Tråvén et al., 2001). Passively derived 
antibodies decrease or delay the active antibody response to infection in calves 
(Heckert et al., 1991). 
 
Vaccination  
Live vaccines 
Live vaccines against respiratory infections in cattle are based on virus strains that 
have been attenuated by extensive passages in cell culture (Wellemans, 1990). 
When administered intramuscularly, these viruses replicate only to a very limited 
extent at the site of injection and probably never reach the respiratory tract (Stott 
et al., 1984). Intranasal administration on the other hand, lead to replication, but 
possibly also to spread to unvaccinated controls (Bryson et al., 1999).  
 
It is recommended to administer live vaccines only to healthy individuals in order 
not to exaggerate the clinical signs of an eventual concurrent infection (Kimman et 
al., 1989). Moreover, the storage is delicate because the vaccine strains may be 
inactivated by heat, freezing or needle disinfectants and freeze-dried products have 
a short life-span once a dissolvent has been added. Maternal antibodies suppress 
the humoral response to vaccination and immunization during this period gives a 
poorer response (Stott, Thomas & Taylor, 1986; Kimman, Westenbrink & Straver, 
1989). Other shortcomings are the risk of reversion to pathogen forms and spread  
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as well as spread of adventitious contaminating pathogens, such as BVDV (Stott et 
al., 1984; Barkema et al., 2001).  
 
Most field studies on the efficacy of vaccines lack good experimental design and 
formal analysis of data (Martin, 1983; Perino & Hunsaker, 1997), but some live 
vaccines against BRSV and BRSV/BHV-1/BVDV (Rispoval and Rispoval 3, 
SmithKline Beecham Animal Health) have shown significant protection in blind 
field trials (Verhoeff & van Nieuwstadt, 1984b; Frankena et al., 1994). Likewise, 
a live BCoV/bovine rotavirus (BRV) vaccine (Calf-guard, Pfizer) induced a 
significant reduction of BRD in calves seronegative for BCoV in a randomized 
blind study with natural BCoV infections (Plummer et al., 2004). 
 
Inactivated vaccines  
Inactivated vaccines, which are virus strains treated with a virus-inactivating agent 
and mixed with an adjuvant, are safer with regard to innocuity and are less 
sensitive to storage. During the inactivation, however, the surface proteins may be 
deformed and may give rise to poor, non-protective and even allergic immune 
responses to a subsequent infection, with poor cytotoxic T-cell activation. This 
vaccine-induced phenomenon have been suggested as the cause of enhanced 
disease upon HRSV infection in children (Openshaw, Culley & Olszewska, 2001) 
and upon natural (Schreiber et al., 2000) and experimental BRSV infection in 
calves (Gershwin et al., 1998; Antonis et al., 2003). The BRSV vaccine that was 
believed to cause enhanced disease upon natural infection also failed to protect 
calves against BRSV two months after vaccination in other herds and was 
consequently withdrawn from the market in 1998 (Larsen, Tegtmeier & Pedersen, 
2001). It is noteworthy that inactivated BRSV vaccines are annually sold in a large 
number of doses and that disease enhancing effects have only been reported once 
from a field situation. Another, perhaps larger hinder to the success of the 
inactivated vaccines is that, like for the live vaccines, the presence of maternal 
antibodies may suppress the humoral response to vaccination. The short duration 
of immunity of some vaccines (Larsen, Tegtmeier & Pedersen, 2001) may lead to 
indefensibly expensive re-vaccination schedules for an optimal effect.  
 
Nevertheless, significant protection was obtained in blind field trials on young 
calves immunised with a inactivated vaccine against BRSV, PIV-3 and 
Mycoplasma spp. (Torvac, C-Vet Veterinary Products) (Howard et al., 1987; Stott 
et al., 1987). The BRSV component in this vaccine is based on glutaraldehyde-
fixed cells persistently infected with BRSV. This component also induced 
significant virological protection against a subclinial experimental infection in 
calves with maternal antibodies against BRSV (Stott, Thomas & Taylor, 1986). 
Another inactivated vaccine, against BCoV, BRV and E. Coli K99 (Lactovac, 
Hoechst), resulted in significantly higher antibody titres in calves during the first 
3-4 weeks of life when administered to cows in the last trimester. The clinical 
effect on calf health, however, has not been thoroughly documented in peer-
reviewed journals (Waltner-Toews et al., 1985; Kohara et al., 1997). No 
respiratory vaccine had been licensed in Sweden until 2004, when an inactivated 
vaccine against BRSV, PIV-3 and M. haemolytica was launched (Bovilis  
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Bovipast® vet., Intervet). To the authors’ knowledge, the efficacy of this vaccine 
has not been evaluated in published field trials. 
   
Immunostimulating complexes (ISCOMs) 
Like Torvac in calves, subunit immunostimulating complexes (ISCOMs) have also 
shown promise in animals with maternal antibodies (Osterhaus, van Amerongen & 
van Binnendijk, 1998). This antigen-delivery system has been used experimentally 
in a variety of species and for a range of antigens (Sjolander et al., 2001; Morein, 
Hu & Abusugra, 2004). Virus ISCOMs are built up of viral proteins, often surface 
proteins, that are incorporated in ISCOM particles of virus-like sizes (40-100nm), 
with inbuilt adjuvance. Spherical particles form spontaneously when cholesterol 
and phospholipids are added to viral antigens and Quil A adjuvant (Morein et al., 
1984). Quil A is a semi-purified preparation of Quillaia saponins from the bark of 
the tree Quillaia saponaria Molina. This adjuvant is commonly used in other 
inactivated vaccines for animals, but has fewer side-effects (local inflammation, 
hemolysis) and induces stronger T-cell responses when administered as ISCOMs 
(Sjolander et al., 2001). Lower Quil A doses are required when using ISCOMs, 
compared to other systems where the adjuvant is not physically linked with the 
antigen (Barr & Mitchell, 1996). 
 
The close association between purified antigens and Quil A in ISCOMs is thought 
to be important in the priming of immunity, possibly due to uptake of antigen and 
adjuvant by the same antigen presenting cells (APCs). ISCOMs enhance cytokine 
production and expression of MHC class II on APCs and stimulate the targeting of 
antigens to lymphoid organs. In addition, they induce strong humoral responses 
with low antigen doses (Sjolander, Cox & Barr, 1998). The adherence of ISCOMs 
to cell membranes is probably reflected by the high affinity of Quil A to 
cholesterol (Barr & Mitchell, 1996). Commercially available ISCOM vaccines 
exist against equine influenza, BVDV and equine gonadotropin-releasing hormone 
and several vaccines against human viruses are in phase I and II clinical trials (B. 
Morein, personal communication). Furthermore, experimental ISCOM vaccines 
against BVDV and BHV-1 have generated very good protection when evaluated 
in sheep and cattle (Trudel et al., 1988; Carlsson, Alenius & Sundquist, 1991; 
Merza et al., 1991). One obstacle to commercial virus-ISCOM production is the 
requirement of large amounts of virus of high titre for purification, if the proteins 
are not artificially produced. 
 
Diagnosis 
The laboratory diagnosis of viral diseases can be made directly, by detection of 
virus, or indirectly, by detection of virus-specific antibodies. 
 
Direct laboratory diagnosis 
Commonly used techniques in direct detection of BRSV, PIV-3 and BCoV are 
isolation of virus in tissue culture, immune based detection of antigens in 
histological sections or body secretions (immunohistochemistry or ELISAs) and 
detection of viral RNA by classic or real-time PCR. Whereas the window of  
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detection for the former techniques is only a few days after the onset of clinical 
signs, the PCR can detect viral RNA during two weeks in optimal cases (Larsen et 
al., 1999; Valarcher et al., 1999; Cho et al., 2001). There are also other 
techniques, such as electron microscopy and haemadsorption, which are more used 
for research purposes than for routine laboratory diagnosis today. 
 
Virus isolation in tissue culture 
A classic method to directly detect BRSV, PIV-3 and BCoV is to isolate virus in 
tissue culture. Difficulties of this approach might contribute to an underestimation 
of the frequency of infections, in particular the type of cells chosen for culture. 
BRSV and PIV-3 are preferably propagated on primary bovine embryonic 
turbinate (Elvander et al., 1998; Valarcher et al., 1999), lung (Bryson et al., 1999; 
Tjornehoj et al., 2003) or kidney cells (Taylor et al., 1995; Adair et al., 1999), 
whereas a human cell-line (human rectal tumour cells, HRT-18) is often required 
for isolation of BCoV (Storz et al., 2000b). The lability of RNA viruses is 
problematic because virus isolation depends on viable virus upon admission to the 
laboratory. Although the method is sensitive under suitable conditions, the number 
of days after infection when isolation is possible is limited. Detection of virus in 
cell culture is based on cytopathogenic effects, such as lysis of cells (BRSV, PIV-
3 and BCoV), syncytia (BRSV, sporadically also for PIV-3 and BCoV); 
intracytoplasmatic inclusions (BRSV and PIV-3) and verification by immune 
based antigen detection (Wellemans, 1990; Viuff et al., 1996). Virus isolation 
always implies a risk of amplification of co-infections that are better gained by the 
culture conditions than the actual pathogen. One main benefit, however, is the 
guarantee that the animal was infectious at the time of sampling. This cannot be 
assured with the techniques described below. 
 
Immune based detection of antigens 
Immune staining is widely used for antigen detection in tissue samples and body 
fluids. In these assays virus-specific antibodies (e.g. polyclonal antibodies from a 
hyper-immunised animal or MAbs) are allowed to attach to antigen in the bovine 
sample and are visualised by enzymatic reactions or by fluorescence (Viuff et al., 
1996). Virus-specific antigen (ag) ELISAs work in a similar way, except that virus 
in the sample attaches to wells coated with virus-specific MAbs before the 
antibodies are added. Rapid pen-side antigen test-kits are available for the 
detection of BRSV (Valarcher et al., 1999). 
 
PCR 
The classical polymerase chain reaction (PCR), which amplifies DNA in a specific 
manner, has improved the sensitivity of the direct diagnosis of viruses 
dramatically (Belák & Ballagi-Pordány, 1993a). This technique relies on the 
design of nucleotide primers that flank a conserved region in the virus genome and 
its complementary sequence. After isolation of RNA and generation of 
complementary DNA (cDNA) by RT, the primers are allowed to hybridize to 
opposite strands in the cDNA. The cDNA denaturates and primers anneal and 
extend at different temperatures so that new templates are formed. By repetitive 
thermocycling, amplicons of similar size accumulate, which are visible by eye 
after processing in an agarose gel and staining. The high sensitivity of this assay is 
also a weakness because complicated laboratory routines are required to avoid  
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sample contamination and amplification of contaminating agens (Belák & Thorén, 
2001). The classical gel-based PCR is labour intensive, which makes it expensive.  
 
Real-time PCR is a refinement of the classical PCR method, in which the post 
PCR processing is omitted. The real-time PCR assay can provide a high sensitivity 
and requires therefore only one round of amplification, which further reduces 
working time and decreases the risk of contamination of samples. The real-time 
PCR is based on a more objective detection of amplicons than the classical PCR 
and it can be used to quantify viral RNA in the original sample (Boxus, Letellier & 
Kerkhofs, 2005). It also allows the simultaneous analyses of up to 96 samples. A 
range of different systems is available to detect amplicons in real-time (e.g. 
TaqMan®, molecular beacon, CYBR Green and Primer-Probe energy transfer), all 
of which generate a fluorogenic signal that can be measured in each cycle. Instead 
of gel-based visualisation of the end product, as in the classical PCR, amplicons 
are objectively quantified in “real-time” by a computer. In the TaqMan® system, a 
probe, labelled with a dye (emitting light) and a quencher (absorbing light), 
anneals between the primers on the cDNA strands. When a Taq polymerase 
elongates amplicons between the primers, the probe is released in fragments so 
that dye and quencher separate. This gives rise to the measurable fluorogenic light. 
 
Indirect laboratory diagnosis 
The indirect laboratory diagnosis is based on detection of virus-specific antibodies 
in body fluids. Although this approach does not precisely determine the time of 
infection, it is applicable for a long period (months to years) after the few days of 
viral shedding in the case of a transient infection. The diagnostic sensitivity is 
therefore greatly improved. Seroconversion between paired samples can be used to 
estimate when the infection occurred (see humoral immunity sections). Adult 
animals with high levels of virus-specific IgG and young animals with high levels 
of maternally derived IgG1 do not always show titre rises after infection, but a 
transient rise in IgM can sometimes be detected in the latter case (Kimman et al., 
1987). For IgG analysis, paired samples should be obtained during the first week 
after the onset of clinical signs and again three to four weeks later, preferably from 
6- to 7-month-old calves (or older animals), which have lost their maternally 
derived antibodies. For IgM analyses, sera are where possible obtained from the 
same age group, within the first or second week after the onset of clinical signs. 
Three commonly used antibody assays are listed below (serum neutralization test, 
and indirect and capture ELISAs). Others are for example haemagglutination-
inhibition assays and blocking ELISAs. 
 
Serum neutralization tests 
Neutralizing antibodies are detected by adding dilutions of sera to a viral 
suspension of a defined concentration (or vice versa, i.e., varying virus 
concentrations mixed with a constant serum concentration) and by inoculating 
these mixtures onto susceptible cell cultures. The highest dilution of antibody that 
protects the cells against destruction from viral infection represents the titre 
(Murphy et al., 1999). The virus growth can be quantified by several means, e.g. 
by observation of cytopathic effect (CPE) by microscopy, or by a plaque-forming 
assay, in which a solid or semi-solid overlay is added to define viral growth into a  
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number of plaques. In the plaque-forming assay, the titre is calculated based on a 
reduction of plaques in comparision with virus controls (Kennedy et al., 1988). 
 
Indirect and capture ELISAs  
Virus-specific antibodies in the sample adhere to viral antigens coated in the 
plastic wells of indirect ELISAs. By adding antibodies directed to the Fc part of 
bovine immunoglobulins (e.g. monoclonal antibodies against bovine IgG) and 
conjugated with an enzyme (e.g. horseradish peroxidase), the presence of virus-
specific antibodies in the original samples may be visualised by a substrate (e.g. 
tetramethylbenzidine in H202) and the reaction stopped by sulphuric acid (Portelle 
et al., 1984; Elvander et al., 1995).  
 
In capture ELISAs, wells are coated with isotype-specific monoclonal antibodies 
against the Fc parts of bovine immunoglobulins. Thereby all antibodies of a 
specific isotype in the sample adhere to the well, regardless of antigen specificity. 
By adding viral antigen and conjugated antibodies against the antigen, virus-
specific antibodies of the addressed isotype are visualized in the sample, as in 
indirect ELISAs (Uttenthal et al., 2000).   
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Aims of the study 
 
The first part of this thesis deals with the incidences and infection dynamics of 
BRSV, PIV-3 and BCoV in Swedish cattle herds. The second part focuses on the 
development of a diagnostic method to detect BRSV and the evaluation of a 
candidate vaccine as well as a commercial vaccine against this virus in vivo. The 
specific aims were to: 
 
•  Investigate seroprevalences and incidences of BRSV, PIV-3 and BCoV a) 
in calves in 118 dairy herds in one area of Sweden and b) in calves 
arriving at a bull testing station from 99-124 Swedish beef-breeding 
herds, in each of six years. 
•  Describe BRD treatment rates in the bull testing station. 
•  Establish a fluorogenic RT-PCR (fRT-PCR) to detect BRSV in clinical 
samples. 
•  Evaluate the immunogenicity and protection induced by BRSV 
immunostimulating complexes (ISCOMs) and a commercial inactivated 
BRSV vaccine (CV) in calves, by using an experimental BRSV 
challenge. 
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Materials and methods 
This section contains a brief explanation of materials and methods used in Paper I-
IV and some methodological considerations. More attention is given to methods 
that are not described in detail in the papers. 
 
Animals, herds and study design 
Paper I  
Paper I comprised 354 heifer calves in 118 dairy herds, selected as described 
previously (Svensson et al., 2003). Briefly, herds in one area of south western 
Sweden were included in the study on the basis of size, rearing systems of heifer 
calves and the farmer’s will and capability to participate in the investigation. The 
herds represented Swedish dairy herds affiliated to the official eradication 
programme for BVDV and that had between 28 and 94 (median 48) cows. Three 
heifer calves per herd were selected based on a recorded history of respiratory 
disease, as described in detail in Svensson et al. (2003). In herds where no calves 
fulfilled the criterion of disease (n=15), animals were randomly selected. 
 
Blood samples were collected from the 354 calves when they were median 7 
months old, during March to May 1999. Additional samples were obtained from 
345 of these animals at median 15 months of age. The sera were analysed for IgG 
antibodies specific to BRSV, PIV-3, BCoV and BVDV. Information was collected 
through interviews with farmers on: i) estimated air-distance to the closest cattle-
rearing herd, ii) purchase of animals during 1998-2000, iii) co-pasturing with 
animals from other herds between samplings and iv) estimated number of visitors 
during an average month. 
 
Paper II 
Animals at a Swedish bull testing station were monitored for viral infections and 
BRD antibiotic treatments during six years. Each year in August (1998-2003), 
149-185 4- to 8-month-old calves arrived at the station from 99-124 different beef-
breeding herds and stayed until March the following year (970 cattle in total). 
Only calves tested free from BVDV were allowed to enter the station and original 
animal groups were kept isolated from cattle three weeks before admission. 
Neither prophylactic antibiotic, nor BRD vaccines were used. The animals were 
kept in 10 semi-outdoor pens generously bedded with straw, in a barn with 3 
walls. The same veterinarian started all treatments throughout the study. 
 
Blood samples were collected on arrival at the station (August), in November and 
by the end of January. Additional sampling was performed in October 2002 and 
2003 and also during outbreaks of respiratory disease or diarrhea. Analyses for 
BRSV, PIV-3, BCoV and BVDV IgG antibodies were performed on sera from all 
animals in 98/99 and 99/00, and on sera from a selection of animals from 00/01 
and on (including animals from all pens).  
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Paper III 
A BRSV fRT-PCR, based on the TaqMan® principle, was developed and 
evaluated on clinical samples. TaqMan® was chosen because this probe is less 
sensitive to point mutations than for example molecular beacons (M. 
Hakhverdyan, personal communication). 
 
Samples for evaluation of the fRT-PCR originated from a number of sources. 
Twenty-eight lung samples derived from Danish BRD field cases and were 
previously tested with ag ELISAs. Moreover, 34 lung samples derived from 
Danish BRSV challenge experiments and were previously tested with ag ELISAs 
and BRSV conventional RT-PCR. Furthermore, 28 nasal swabs from the 
experimental study in Paper IV were used, which had previously been tested with 
BRSV nested RT-PCR and/or virus isolation. Eleven swabs (and paired sera) from 
three Swedish dairy herds with outbreaks of BRD, nine BRSV strains and eight 
symptomatically or genetically related virus species were also tested.  
 
The oligonucleotide primers (19 and 25 nucleotides) and probe (34 nucleotides) 
against BRSV were designed from the published sequence of the F gene of isolate 
394 (GenBank accession No. AF188554) and the predicted product size of the 
BRSV amplicon was 85 base pairs. Compatible primer sets were selected to ensure 
efficient amplification and detection of BRSV isolates from all six phylogenetic 
subgroups (Valarcher, Schelcher & Bourhy, 2000). The fRT-PCR was optimised 
by titration series of primers, probe and Mn
2+. Analyses were carried out on an 
ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, 
CA, USA). 
 
A ten-fold dilution series of a BRSV positive RNA template (three dilutions, five 
replicates of each dilution) were used to generate a standard curve and to calculate 
the reaction efficiency. In addition, the detection limit of the fRT-PCR was 
compared to that of nested RT-PCR, by testing nine steps of a ten-fold dilution 
series of a BRSV strain (No. 9402022) (Viuff et al., 1996). The reproducibility of 
the fRT-PCR was assessed by testing 62 samples in duplicate. 
 
Paper IV 
For the challenge experiment in Paper IV, 14 conventionally reared Swedish Red 
and White breed male calves were obtained from a closed dairy herd, certified as 
free from BVDV infection under the Swedish control programme on BVDV. The 
calves were matched into three groups according to age and BRSV-specific serum 
IgG1 levels. Two groups of 5 calves each were immunised subcutaneously (s.c.), 
twice with three weeks interval, with either an experimental subunit BRSV 
vaccine (ISCOMs) or with a commercial inactivated BRSV vaccine (CV). Four 
calves were left as unvaccinated controls. The age of the calves at the day of first 
immunization ranged between 52 and 105 days and the mean age in each group 
was 78 (ISCOM), 85 (CV) and 86 days (controls). The mean maternally derived 
BRSV-specific serum IgG1 titres were 3.6 log10 for both vaccine groups and 3.7 
log10 for the controls. After arrival at the Dept. of Ruminant Medicine and 
Veterinary Epidemiology, animals were kept group-wise in three pens divided by 
floor-to-roof walls.  
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Three weeks after the second immunization, all calves were challenged with 3 x 
10
4.5 TCID50 of a seventh passage BRSV strain (no. 9492922, Denmark) (Viuff et 
al., 1996). The inoculum was administered by aerosol inhalation, essentially as 
described earlier (Tjornehoj, 2000), except that no intra-tracheal injections were 
made. Virus inoculated foetal bovine lung cells were harvested with cell scrapers 
and treated with ultrasound. Visual examination in light microscope after 
treatment revealed many rounded, separated cells and that some cells were lysed. 
One aliquot were kept in the inoculation facilities during the inoculation and was 
thereafter titrated, in order to assure the virus stability throughout the inoculation.  
 
A veterinarian, blinded as to treatment group, performed daily clinical 
examinations and nasal sampling for virus detection, from the day of challenge 
(day 0) to day 10. Sera were obtained on 14 occasions throughout the study and 
were analysed for BRSV-specific antibodies of several isotypes. Sera from day 30 
was additionally analysed for BVDV-specific IgG antibodies. 
 
Virus detection 
Virus isolation  
Isolation of BRSV from experimentally infected animals was attempted in Paper 
IV and these samples were also used as a part of the evaluation of the fRT-PCR in 
Paper III. Nasal cotton swabs in 1 ml F-DMEM, containing 20% gamma-
irradiated foetal bovine serum were collected on day 3, 4 and 5 after infection and 
were immediately analysed, on a daily basis. Day 3, 4 and 5 were chosen because 
high levels of virus shedding were predicted on these days, thus increasing the 
probability of getting positive results from immunised animals. Because freezing 
might result in loss of virus infectivity (K Tjornehoj, doctoral thesis 2000), virus 
isolations were performed with fresh material filtered through a 45-µm filter onto 
a large cell surface (25cm
2). Virus isolations and PCR were performed on different 
swabs from the same animal (Virocult®, Medical Wire and Equipment Co Ltd. 
England, for PCR and cotton swab in medium and 20% FBS for virus isolation) 
and the swabs used for PCR were not filtered. It is possible that some infectious 
virus was lost during the filtration of sample material; however, it is more likely 
that results from samples negative in virus isolation and positive in PCR simply 
reflected a higher sensitivity of the PCR.  
 
Antigen ELISA  
A BRSV-specific ag-ELISA was used in Paper III, as previously described 
(Uttenthal, Jensen & Blom, 1996). Briefly, wells were coated with bovine anti-
BRSV Ig extracted from hyperimmune sera or Ig from BRSV antibody negative 
sera (controls). After incubation of samples, biotinylated bovine hyperimmune 
anti-BRSV Ig, peroxidase-conjugated avidin and orthophenylenediamine substrate 
were added. The reaction was stopped with sulphuric acid. Plates were washed 
between each step. 
 
RT-PCR  
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Precautions for contamination 
Routine precautions and safety measures to avoid contamination of samples in our 
laboratory are described elsewhere (Belák & Ballagi-Pordány, 1993b). Briefly, 
five different rooms were used for i) handling of clean stocks ii) preparation of 
RNA and cDNA iii) performing PCR iv) preparation of nested PCR and v) gel-
electrophoresis. Different coats, sample racks and pipettes were used in all rooms 
and gloves, racks and samples were never taken between rooms against the flow 
system. Disposable tubes were autoclaved before use and opened with opening 
tools, which were kept in 10% chloride between uses. Laminar flow cabinets were 
cleaned with chloride and exposed to UV radiation and aerosol-resistant tips were 
used at all steps.  
 
RNA isolation for nested and fluorogenic RT-PCR 
Total RNA was extracted from nasal swab media, faeces diluted in PBS or 
homogenated tissue. In brief, 250 µl sample material were mixed with 750 µl 
TRIzol LS Reagent (Invitrogen, USA; containing phenol and guanidine 
isothiocyanate) and incubated for 5 min at room temperature (to lyse cells and to 
disrupt nucleoprotein complexes, under inhibition of RNAse activity). Thereafter, 
200 µl chloroform was added, mixed and centrifuged at 12 000 x g (Sigma, 
Germany) for 15 min (to separate nucleic acids from viral and cellular proteins). 
The aqueous phase was transferred to a new tube with 500 µl isopropanol and 
incubated overnight at -20°C (for RNA precipitation). After centrifugation at 
12 000 x g for 20 min at 4°C and washing with 1 ml of -20°C 80% ethanol, the 
pellets were air dried, dissolved in 30 µl of dimethylpyrocabonate (DMPC) water 
and stored at -20°C.  
 
Reverse transcription for nested PCR 
Complementary DNA (cDNA) was constructed from 5 µl RNA in 5 µl DMPC 
water, by first denaturating RNA aggregates in the presence of 1 µl random 
hexamers (0.02 U), for 10 min at 65°C and cooling on ice. Thereafter, the 
hexamers were extended for 90 min at 37°C by 1 µl Moloney murine leukaemia 
virus reverse transcriptase (200U), in the presence of 2.5 µl deoxynucleotide 
triphosphates (dNTPs, 2mM), 5 µl 1
st standard buffer and 1 µl RNAse inhibitor 
(RNAguard, Amersham Biosciences). The enzyme was then inactivated for 5 min 
at 95°C. 
 
Nested RT-PCR 
Nested BRSV and BCoV RT-PCR were used in Paper II, III and IV. As 
previously described (Vilcek et al., 1994), these assays amplified conserved 
regions of the F protein coding part of the BRSV genome (711 and 481 basepairs, 
bp) and of the HE protein coding part of the BCoV genome (560 and 407 bp). 
 
Briefly, the PCR mix contained 24 µl DMPC water, 5 µl 10xPCR buffer (Perkin-
Elmer), 1 µl dNTPs (10mM), 5 µl BSA, 1.5µl of each primer, 5 µl MgCl2
 (25mM), 
2 µl Taq DNA polymerase (Ampli Taq, Perkin-Elmer, diluted 1:10) and 5 µl of 
cDNA. Two drops of mineral oil were added to overlay the reaction mix. The 
thermocyling profile included initial denaturation at 94°C for 2 min, followed by  
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35 cycles of denaturation at 94°C for 45 s, annealing at 50°C for 60 s, and 
extension at 72°C for 90 s, followed by a final extension at 72°C for 7 min. An 
internal primer set was added for a second PCR and each cDNA amplicon was 
further amplified as above. The PCR products were processed by gel 
electrophoresis (for verification of the size of amplicons) and visualised by 
ethidium bromide under UV light (Vilcek et al., 1994). A conventional BRSV RT-
PCR was used for comparative studies in Paper III, as previously described 
(Larsen et al., 1999).  
 
Antibody detection 
Serum neutralisation tests  
Neutralising antibodies were detected by a plaque reduction assay, in which 
dilutions of deconjugated sera were mixed with a viral suspension (50-100 plaque 
forming units, PFU, Snook strain) and incubated for 1 h at room temperature. The 
mixtures were thereafter inoculated onto foetal calf kidney cells and incubated 
during 1 h at 37°C (in 6-well plates, samples were run in duplicate). After removal 
of the virus/serum mixtures, the cells were overlayed with medium including 2% 
agarose. Viral growth was defined into a number of plaques after 7 days 
inoculation at 37°C, fixation and staining (Kennedy et al., 1988). The endpoint 
titres were calculated by linear regression analyses and determined as the dilutions 
that produced a 50% reduction in the mean number of plaques compared with 
virus control wells. 
 
Indirect IgG ELISAs 
Commercially available indirect ELISAs (SVANOVA Biotech®, Sweden) were 
used to detect BRSV, PIV-3, BCoV and BVDV-specific IgG in Paper I-IV. A 
single dilution of samples were analysed (1:25, milk undiluted) and the cut-off set 
to a corrected optical density (COD) value of 0.2  (milk 0.05) at 450nm, as 
previously described (Niskanen et al., 1989; Alenius et al., 1991; Niskanen et al., 
1991). Seroconversions were defined as a conversion from a negative to a positive 
COD value in paired samples. When investigating serum antibodies in dairy calves 
in Paper I, an animal was considered infected if it was seropositive in a sample 
obtained at ~7 months of age and remained positive at ~15 months of age. This 
definition was set to exclude animals with remaining maternal antibodies at the 
first sampling, which then decreased to negative. Herds were considered infected 
if at least one sampled animal was infected according to the above definition. 
    
Because the IgG subtype specificity of the commercial indirect ELISAs was 
unclear, additional indirect BRSV-specific IgG1 and IgG2 ELISAs were used for 
the vaccine evaluation in Paper IV. Briefly, the BRSV Snook strain (Thomas et 
al., 1998) and control antigen (calf kidney cell lysate) were diluted with deionised 
water (1:50), were added to a 96-well immunoassay plate (50 µl/well) and were 
left to dry overnight at 37°C. After blocking of unspecific binding with 5% pig 
serum (ps) and between each incubation step, the wells were washed with PBS 
and 0.05% tween 20 (PBS/tween), four times. Sera were serial three-fold diluted 
with ps/PBS/tween (starting on 1:30), 50 µl of each dilution were added to control  
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and antigen wells and incubated at room temperature for 1h. One row was left as 
background control. After washing, MAbs against bovine IgG1 (B37) or IgG2 
(B192), and thereafter horseradish peroxidase (HRP) conjugated goat anti-mouse 
IgG (Sigma), were added and incubated at room temperature for 1 h each. 
Tetramethyl benzidine was used as substrate and the reaction stopped with 2M 
H2SO4. ELISA titres were calculated after subtraction of the OD with control 
antigen from OD with BRSV antigen and plotting of this COD against sample 
dilution. By regression analysis of the linear part of this curve, the end point was 
deduced at an OD that was 1.5 times the background. 
 
IgA and IgM immunocapture ELISAs  
For the vaccine evaluation in Paper IV, BRSV-specific IgA and IgM were 
analysed with immunocapture ELISAs. As previously described in detail 
(Uttenthal et al., 2000), wells were coated with MAbs against bovine IgA and IgM 
(16-35 and 17-3) and sera added in single dilutions (1:20 in PBS/tween, 500µl/l). 
The BRSV strain 88Lu195 (Larsen et al., 1998), biotin conjugated rabbit serum 
against HRSV, HRP conjugated avidin and ortho-phenylen diamine were further 
used for antibody detection. The immunocapture ELISAs were chosen because of 
a lowered risk of saturation of the antigen by the dominating antibody isotype 
(IgG), which is known to decrease the sensitivity of indirect ELISAs during 
detection of antibody isotypes in minority (e.g. IgM) (Graham et al., 1999). The 
IgM assay has previously been used to detect BRSV serum antibodies from day 6-
10 until day 16-17 after experimental infections and three weeks apart after natural 
infections, suggesting a high sensitivity (Uttenthal et al., 2000). BRSV-specific 
serum IgA was only detected in one of three experimentally infected calves (day 9 
to 26) and in two of six naturally infected calves, suggesting a lower sensitivity 
(Uttenthal et al., 2000).  
 
Data analysis 
The
2 χ -test, a two-tailed Students t-test and the Fisher’s exact test were used for 
statistical analysis. 
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Results  
Virus epidemiology (Paper I and II) 
Paper I  
The seroprevalences of BRSV, PIV-3 and BCoV were investigated in young 
animals in 118 dairy herds in one area of Sweden. The observed data were 
generally homogenous in each herd, so that no or all sampled animals were 
seroposititve to respective virus. In 70% (BRSV), 68% (PIV-3) and 82% (BCoV) 
of herds with one ~7-month-old calf seropositive for respective virus, all three 
sampled animals were positive. These figures rose to 80% (BRSV), 83% (PIV-3) 
and 97% (BCoV), when animals were ~15 months old.  
 
The results showed a lowest seroprevalence for BRSV and highest for PIV-3. In 
total, 30% of the ~7-month-old calves were seropositive for BRSV, 48% for PIV-
3 and 34% for BCoV. The incidence of infections between samplings was also 
lowest for BRSV, but highest for BCoV: seroconversions to BRSV, PIV-3 and 
BCoV occurred in 26%, 38% and 50% of seronegative animals (n=242, 177 and 
228) and in 31%, 39% and 48% of negative herds (n=84, 56 and 77). Only six 
herds were classified as negative for all three infections and also BVDV in both 
samples. BCoV infections were statistically more common in BVDV positive than 
in BVDV-negative herds in the second sample (94% vs. 61%, P=0.01, Fisher’s 
exact test). All herds had BRSV and BCoV antibody-positive bulk tank milk and 
38% of herds had BVDV antibody-positive bulk tank milk in 2000.  
 
No significant association was found between purchases of animals, co-pasture 
with animals from other herds or the estimated number of visitor per month. 
However, herds with an estimated air-distance of >1.0 km to the closest cattle-
rearing herd were at significantly lower risk to be classified positive for BCoV at 
first sampling, compared to herds in more densely populated areas (P= 0.03, x
2-
test). In addition, there appeared to be a geographical clustering of infected herds 
and of herds in which seroconversions occurred.  
 
Of 18 herds, in which paired samples were obtained between March and August 
(outside the peak period when BRD is most often seen), seroconversions to 
BRSV, PIV-3 and BCoV were observed in 3 (17%), 4 (22%) and 1 (6%), 
respectively. A significantly higher proportion of herds in which no calves had a 
recorded history of respiratory disease (n=15) were classified as negative to the 
four infections at first sampling, when compared to herds in which disease was 
observed (60% vs. 14%, P=0.0002, Fisher’s exact test). 
 
Paper II 
As observed in the dairy herds, the seroprevalence on arrival at the bull testing 
station from beef-breeding herds (i.e. reflecting infections in the original herds 
before sampling), was lowest for BRSV (37-46%), highest for PIV-3 (51-75%) 
and in-between for BCoV (39-65%). The seroprevalence for PIV-3 on arrival was 
significantly lower in 2002 than in 1998 (P≤0.01,  x
2-test). All seronegative 
animals seemed to seroconvert concurrently when a virus was introduced at the  
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bull testing station. PIV-3 and BCoV infections occurred in 6 of 6 years whereas 
BRSV occurred only every second year (3 of 6 years). Thus, just as in the dairy 
herds, both the seroprevalence and incidence were relatively lowest for BRSV. 
 
There was some evidence that the infections occurred outside winter period. PIV-
3, and occasionally also BRSV and BCoV, occurred in the early autumn (between 
August and October or November) and some calves born in April were shown to 
be infected with BRSV and BCoV before arrival at the end of August.  
 
BRSV was involved in an outbreak of BRD at the bull testing station during the 
winter 99/00, with high treatment rates and fatal disease. In contrast, when BRSV 
was introduced in August 2003 and between November and January 01/02, the 
treatment rates remained low. PIV-3 or BCoV was never associated with high 
BRD treatment rates, but seronegativity to either of these viruses was significantly 
correlated to BRD treatment in Charolais calves, during one year when BRSV was 
absent. Younger calves were at significantly higher risk of being treated during the 
BRSV outbreak (P=0.01, students t-test), but not throughout the whole study 
period.  A difference in treatment rates for breeds was observed, with higher 
treatment rates for Aberdeen Angus and Hereford. 
 
Fluorogenic RT-PCR to detect BRSV (Paper III) 
The single tube BRSV fluorogenic RT-PCR (fRT-PCR) was shown to be a 
sensitive, specific and rapid tool to detect BRSV in both naturally and 
experimentally infected animals. Whereas all BRSV isolates and serologically 
confirmed field cases were tested positive, genetically or symptomatically related 
viruses, interspersed water controls and samples from healthy animals were all 
tested negative. Furthermore, samples that were tested in duplicate were in 
complete accordance, suggesting a good reproducibility.  
 
The fRT-PCR detected four more positive samples than ag-ELISA, three more 
than conventional RT-PCR and two more than virus isolation. Only nested RT-
PCR detected one more positive sample than fRT-PCR. When testing ten-fold 
dilution series of a BRSV cell culture isolate, however, the nested and the fRT-
PCR had similar detection limits. By including rTth DNA polymerase, which 
functions both as a reverse transcriptase and a DNA polymerase, RT and PCR 
were performed in the same reaction tube in the fRT-PCR. The assay required less 
than 3 h to complete, compared to 7-8 h for the separate RT and nested PCR 
assays. In addition, no post PCR handling of products was required. 
 
BRSV-ISCOMs as vaccine candidate (Paper IV) 
Clinical protection 
Whereas all four unvaccinated controls and all five calves immunised with the CV 
developed respiratory disease, none of the five calves immunised with ISCOMs 
were clinically affected after BRSV challenge. 
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The four unvaccinated controls with and without detectable maternal IgG1 
antibody titres at the day of challenge (titres of 0, 2.5, 2.6 and 3.0 log10) developed 
severe disease, confirming the Danish infection model to be reproducible. Peak 
rectal temperatures and respiratory rates in these animals ranged between 39.5-
41.2ºC and 80-120 min
-1 (mean 40.3ºC and 97 min
-1), within six days after BRSV 
challenge. Two controls that showed pronounced abdominal breathing and that did 
not respond to antibiotic and anti-inflammatory treatments were euthanized on day 
6 after challenge, for humane reasons, and BRSV was detected in their lungs 
(immunostaining and fRT-PCR). The two remaining controls developed marked 
lethargy along with respiratory signs that were still present by the end of the 
experiment (day 10). These animals showed BRSV-specific serum IgM and IgA 
antibodies from day 10 and 12.  
 
The severity of the challenge was emphasized by inducing moderate to severe 
respiratory disease also in all five calves vaccinated with the CV. The peak rectal 
temperatures and respiratory rates in this group ranged between 39.4-40.8ºC and 
60-100 min
-1 (mean 40.0ºC and 78 min
-1) after challenge and the severity of 
disease appeared to be directly related to levels of maternally derived BRSV-
antibodies at vaccination. 
 
In sharp contrast to controls and animals vaccinated with the CV, the five ISCOM 
vaccinated animals remained healthy after challenge. They had peak rectal 
temperatures and respiratory rates ranging between 39.3-39.7ºC and 52-56 min
-1 
(mean 39.5ºC and 54 min
-1). These results show a strong clinical protection 
induced by ISCOMs. All calves were seronegative to BVDV on day 30, inferring 
that the challenge isolate was BVDV free. 
 
Rapid humoral responses  
Two doses of ISCOMs induced a 10 to 1000-fold increase of serum IgG1 in all 
animals within 32 days after the first vaccination (by the day of challenge, day 0). 
In contrast, two doses of the CV induced a 100-fold increase only in the animal 
with the lowest levels of maternal antibodies at vaccination. Two animals 
immunised with the CV showed less than a 10-fold increase and the two with the 
highest levels of maternal antibodies at vaccination did not show an antibody 
increase before challenge. Both nasal IgG and serum IgG of both subtypes were 
significantly higher in animals vaccinated with ISCOMs vs. CV on day 0 and 5. 
Furthermore, only the ISCOMs seemed to prime a rapid serum IgA response after 
challenge. 
 
Virological protection 
After experimental challenge, BRSV was re-isolated from the nasopharynx of all 
controls and from all calves immunised with CV, but from none of the calves 
immunised with ISCOMs. BRSV-RNA was detected by fluorogenic and nested 
RT-PCR from a single animal immunised with ISCOMs and from all animals in 
the other two groups. As measured with virus isolation, the virus shedding 
appeared to be directly related to maternal antibodies at vaccination in animals 
vaccinated with the CV.  
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Discussion 
The most critical aspects in the control of BRD are probably the assurance of 
adequate intake of high-quality colostrum and improvement of other management 
and environmental factors that may impair the animals’ immune responses to 
infections (e.g. hygiene, ventilation and nutrition). Another crucial factor is the 
animals’ exposure to pathogens. Entry of new pathogens into herds should be 
reduced and susceptible young animals should be protected from exposure to large 
doses of different pathogens within the herds. Extensive knowledge on pathogen 
transmission and epidemiology is required to intervene in the transmission by 
management. When this information is insufficient and when the management is 
optimized without satisfactory results, vaccination with efficient vaccines could be 
an alternative in herds with substantial losses. 
 
Before initializing costly vaccination programmes against bovine respiratory virus 
infections, it is important to understand their prevalence in the cattle population. 
The incidence rates of infections as well as the impact of the diseases on farmers 
finances and on animal welfare should be considered to compare costs and 
benefits with vaccination. There is also a need to objectively investigate vaccine 
efficacy in the target animal group against natural virus challenge. In addition, for 
any control strategy that aims to reduce the infections on a longer perspective (e.g. 
reduction of virus circulation by vaccination of strategic animal groups or by 
prevention of virus transmission through management), knowledge on the 
following is important: i) modes of virus transmission by direct and indirect 
routes, ii) virus survival in the environment, iii) natural inter-species transmission, 
iv) the importance of reinfections, v) virus latency and re-activation and vi) 
chronic infections. The data accumulated in this thesis give some valuable 
information on the appearance of BRSV, PIV-3 and BCoV in Swedish cattle, on 
BRSV diagnosis and on the efficacy of BRSV vaccination.  
 
Virus epidemiology 
Virus dynamics 
Seroprevalences of infections were assessed in young animals in middle-sized 
dairy herds in one area of southwestern Sweden. In agreement with previous 
studies (Verhoeff & van Nieuwstadt, 1984a; Houe, 1992), the serological results 
in herds were extensively homologous, indicating that the spread of viruses within 
herds is efficient. As also previously suggested (Houe, 1992), this feature allowed 
data from a small number of animals to be interpreted as an infection status of 
each herd. The serological data on BVDV differed from the other viruses as data 
were less homologus in BVDV-positive herds, probably due to a less efficient 
spread of BVDV within herds. The spread of BVDV within herds was possibly 
also affected by early removal of PI animals within the control programme.  
 
It became obvious that PIV-3 and BCoV had circulated in a large number of the 
dairy herds before samplings. In contrast, BRSV infections appeared to be less 
common. Serum antibodies of sampled animals roughly reflected infections in  
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herds during the lifetime of the animals (5-11 months), although some antibodies 
might have been maternally derived and although some infections obtained at 
early age might have been missed due to the suppressive effect of maternal 
antibodies on humoral responses (Kimman, Westenbrink & Straver, 1989; Heckert 
et al., 1991; Graham et al., 1999; Uttenthal et al., 2000). Maternal antibodies to 
BRSV and BCoV have been observed to remain until on average 3.3 and 5 (max 7 
and 6) months of age in dairy calves (Baker, Ames & Markham, 1986; Alenius et 
al., 1991) and to BRSV and PIV-3 until on average 6.2 and 6.3 (max 7.3 and 8.5) 
months of age in suckling beef cattle (Fulton et al., 2004). Thus, most of the 
maternal antibodies were assumed to have declined by the first sampling. High 
incidences of the infections were confirmed by frequent seroconversions between 
paired samples.  
 
Seroprevalences of the infections were also assessed in 4- to 8-month-old calves 
originating from a number of beef-breeding herds throughout Sweden, on arrival 
at a bull testing station. As interpreted from serum antibodies on arrival, PIV-3 
seemed to be more prevalent than BCoV and BRSV in the original herds, 
supporting the data from the dairy herds. At the bull testing station, the number of 
calves with antibodies to PIV-3 on arrival was significantly lower in 2002 than in 
1998, which might have been an effect of bio-security measures within the 
national control programme against BVDV. Only 25% of beef herds that were 
registered in the programme in July 1998 were declared free from BVDV, as 
compared with 90% in July 2002 (Data obtained from the Swedish Dairy 
Association). Both PIV-3 and BCoV circulated annually at the bull testing station, 
whereas BRSV showed the lowest incidence; it circulated only every second year. 
This information complements previous nationwide studies on bulk tank milk, 
which show that BRSV and BCoV are widely spread in Sweden (Elvander, 1996; 
Tråvén, Bjornerot & Larsson, 1999). 
 
Because the cattle density is lower in Sweden than in many countries and because 
some bio-security measurements might be higher due to our BVDV control 
programme, the incidences can be expected to be even higher in other parts of the 
world. It is difficult to interpret serologic data from countries where vaccination is 
commonly used; however, annual BRSV and PIV-3 infections have been observed 
in Dutch dairy herds (Verhoeff & van Nieuwstadt, 1984a; Van der Poel et al., 
1993) and 62-100% of 6- to 9-month-old beef cattle were seropositive to BCoV on 
arrival at feedlots in Canada and USA (Martin et al., 1998; Plummer et al., 2004). 
In addition, 100% of sampled Brittish herds that did not use vaccination (n=341) 
were BRSV and BCoV antibody positive in bulk tank milk (Paton et al., 1998), 
compared to 41-89% (BRSV) and 70-100% (BCoV) of herds in nationwide 
Swedish studies (northern and southern parts of the country) during the 1990s 
(Elvander, 1996; Tråvén, Bjornerot & Larsson, 1999). 
 
Disease 
BRSV was previously shown to cause severe clinical signs of respiratory disease 
in Swedish cattle (Elvander, 1996) and this virus was also involved in an outbreak 
of BRD at the bull testing station during the winter 99/00. At this time, most of the 
animals in the herd had become seronegative for BRSV. Therefore, many  
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individuals probably shed large amounts of virus, which increased the infection 
dose for other susceptible herd mates. Interestingly, when the infection was 
introduced in August 2003 and between November 2001 and January 2002, the 
treatment rates remained low, confirming earlier observations that many BRSV 
infections are asymptomatic (Verhoeff & van Nieuwstadt, 1984a; Van der Poel et 
al., 1993). Possibly, strains with different virulence were circulating in the 
different years and the plausible higher herd immunity and the climate in August 
2003 influenced the virus dose to naive individuals. A dairy herd (herd A, Paper 
III) with naïve adult cows suffered from a clinical BRSV outbreak in August, 
suggesting that the season does not play a definitive role on the clinical outcome 
of BRSV infections. 
 
High BRD treatment rates were not observed during periods when PIV-3 and 
BCoV infections occurred at the bull testing station. However, Charolais calves 
that were seronegative to either of these viruses on arrival were at significantly 
higher risk to receive BRD treatment, compared to seropostitive calves, during one 
year when BRSV was absent. Both PIV-3 and BCoV have previously been 
associated to BRD treatments (Stott et al., 1980; Storz et al., 2000a; Plummer et 
al., 2004), and also, a significant association was obtained between absence of 
BRSV, PIV-3, BCoV and BVDV with absence of BRD in calves in the dairy 
herds. The disease caused by these viruses is probably more severe during harder 
environmental conditions, larger infection pressure (including additional 
infections) and lower herd immunity than during those studied at the bull testing 
station. It is important to further investigate the clinical impact of these infections, 
especially in Swedish fattening herds, which introduce young animals in a 
continuous manner.  
 
Transmission 
Based on the geographical proximity of infected dairy herds and on numerous 
infections in dairy herds that did not introduce new animals, the results indicated 
that indirect spread is an important way of virus transmission. Moreover at the bull 
testing station, BRSV and BCoV infections occasionally occurred without 
introducing animals. BRSV was probably introduced from outside, since cattle on 
a neighbouring farm showed similar disease prior to the outbreak. Undoubtedly 
BRSV and BCoV may spread rapidly over large areas and into herds without 
livestock trade (unpublished observations of outbreaks in herds with naïve adult 
animals, Sweden); nevertheless, this does not rule out latency and re-activation of 
virus in certain previously infected herds. It should be emphasized that the latter 
phenomenon has never been demonstrated. A significant association was obtained 
between herd air-distances and BCoV in the dairy herds, which may have been 
due to increased direct or indirect (human) contacts between neighbouring herds, 
of spread by small vectors (rodents, birds) or even by air. BCoV differs from 
BRSV and PIV-3 in that it is also shed in faeces and this is probably an important 
factor for its survival and transmission. Airborne spread between buildings have 
been described for SARS-CoV (Yu et al., 2004) and porcine respiratory CoV 
(Stärk, 1999). 
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No significant association was obtained between the estimated number of visitors 
per month and dairy herd infection status in Paper I. However, all herds were 
visited by milk tanker drivers and all had at least one additional visit per month. A 
control group without visitors was thus not included. It is likely that the infections 
spread by humans (Wellemans, 1990; Callan & Garry, 2002) and outbreaks in 
closed herds are often preceded by visits (unpublished observations). It is 
therefore crucial to perform studies on how to prevent transmission by man. Data 
on this topic would be useful, especially for the protection of naïve herds in 
isolated parts of Sweden. 
 
In contrast to BRSV and BCoV, PIV-3 virus was introduced on all six occasions 
when animals were commingled at the bull testing station in August. Quarantine 
procedures and commingling during summertime did not prevent the transmission 
of this infection. It appears therefore that PIV-3 is more easily transmitted than 
BRSV and BCoV, or circulates to a higher extent all year around. This is also in 
accordance with the different infection pattern observed in the dairy herds, where 
PIV-3 infected herds were distributed throughout the area, whereas BRSV and 
BCoV did not reach certain sub-areas. Indeed, PIV-3 also showed a higher 
prevalence. 
 
Possible modes of prevention 
Eradication  
Several modes of prevention of viral infections in cattle are used in different parts 
of the world. The most drastic approach is eradication of pathogens, which 
currently is applied for BVDV in Scandinavia (Lindberg & Alenius, 1999). This 
method requires detailed information on virus transmission and epidemiology in 
the cattle population. Eradication of virus without knowledge on how to prevent 
transmission might be hazardous (if possible), considering the risk of re-
introduction of virus. Keeping in mind that areas with cattle naïve to BRSV have 
suffered large losses from BRSV outbreaks (Inaba et al., 1972; Elvander, 1996), 
eradication will not be an alternative for BRSV, PIV-3 or BCoV until extensive 
data on how to prevent their spread is produced. Such research would also be 
essential for the design of control strategies.  
 
A key factor that distinguishes BRSV, PIV-3 and BCoV from BVDV, and that 
makes eradication programmes against these viruses less likely to become 
successful, is their efficient transmission (probably both directly and indirectly) by 
transiently infected animals. Hypothetically, the infection dose for BRSV, PIV-3 
and BCoV is much lower than for BVDV since transiently BVDV infected 
animals do not appear to transmit the virus to susceptible pen mates. Moreover, 
airborne transmission of BVDV may be prevented by walls within a building 
(Niskanen et al., 2000; Niskanen, Lindberg & Traven, 2002; Niskanen & 
Lindberg, 2003). BVDV is mainly spread by PI animals that acquire the infection 
in utero and that shed large amounts of virus throughout their life. As shown in the 
dairy herds in Paper I, the spread of BVDV between herds is low when these 
animals are identified and slaughtered; when pregnant animals are protected from 
contact with PI animals and when herds are prevented from introducing PI animals  
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or cows pregnant with PI animals (Lindberg & Alenius, 1999). Besides isolation 
of calves from new cattle, the application of virus and antibody detection before 
arrival at the bull testing station in Paper II was shown sufficient to prevent 
BVDV in this herd. 
 
As an alternative to obligatory eradication programmes, attempts to prevent 
introduction of new infections can be made on a herd basis according to the wish 
of each farmer. When prevention is successful, established infections will most 
likely be self-cleared, as have been observed for BRSV, BCoV and BVDV 
(Alenius et al., 1991; Elvander, 1996; Lindberg & Alenius, 1999). One important 
aspect, however, is how to protect these herds from new introduction of virus, 
since the herd immunity will decrease from the moment the infection is cleared. If 
costs do not exceed benefits, these animals should perhaps be protected by 
vaccination. 
 
Vaccination 
This section focuses only on vaccination against BRSV because it is largely 
involved in severe BRD in Swedish cattle. Until 2004, no BRSV vaccine had been 
licenced for use in Sweden, partly because published data on the protection 
induced by commercial vaccines against natural challenge was sometimes 
disappointing or uncertain (Martin, 1983; Perino & Hunsaker, 1997; Schreiber et 
al., 2000; Larsen, Tegtmeier & Pedersen, 2001). Moreover, one Swedish field trial 
showed enhanced disease after vaccination with a commercial inactivated 
multivalent vaccine (PIV-3/ M. Haemolytica/ P. Multocida/ BVDV, S Alenius and 
M Törnquist unpublished observations).  
 
The experimental BRSV model 
By using an infection model that is previously evaluated in conventional calves 
with varying levels of maternal antibodies to BRSV (Tjornehoj, 2000), severe 
disease was reproduced in unvaccinated calves with and without maternal 
antibodies in Paper IV. A similar degree of disease has been published with other 
models, but only after challenge in seronegative calves (West et al., 1999; 
Woolums et al., 1999). Experimental challenge in calves with maternal antibodies 
has previously induced mild or no clinical signs (Belknap et al., 1991; Patel & 
Didlick, 2004; Mawhinney et al., 2005). To our knowledge, Paper IV is the first 
report of a BRSV vaccine evaluation against an experimentally induced severe 
disease in animals with maternal antibodies.  
 
Protection against virus shedding and clinical signs 
The most notable result in Paper IV was the absence of virus shedding after 
infection in 4 of 5 BRSV-ISCOM vaccinated calves as determined by PCR (5 of 5 
as determined by virus isolation). Reduced virus shedding has been observed 
before for other vaccines administered to calves with maternal antibodies, but only 
after challenge causing mild or no disease and by virus isolation attempts (Stott, 
Thomas & Taylor, 1986; Patel & Didlick, 2004; Mawhinney et al., 2005). Full 
protection against virus shedding determined by the more sensitive fluorogenic 
and nested RT-PCR, together with severe disease in controls, has, to the author’s  
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knowledge, never before been demonstrated. This finding suggests that the 
ISCOMs can be used to stop virus circulation within and between herds. All 
calves vaccinated with the CV shed virus in the same experiment, as determined 
by both virus isolation and PCR. 
 
Importantly, the clinical signs after challenge were also completely absent in 
calves vaccinated with BRSV-ISCOMs. Both virus shedding and the severity of 
signs in calves vaccinated with the CV appeared to be directly related to their 
maternal antibody status at vaccination and inversely related to antibodies at 
challenge. The two calves with highest levels of maternal antibodies at vaccination 
thus developed the most severe disease. Although the calf with lowest levels of 
maternal antibodies in the ISCOM group developed the strongest IgG and 
neutralizing antibody response, the ISCOMs overcame the suppressive effect of 
maternal antibodies on the response to vaccination in all animals. A disease 
enhancing effect was not observed. 
 
The protection of single shots of live (Rispoval; Pfizer Animal Health) and 
inactivated (Bovipast; Intervet) vaccines in 4- to 5-week-old calves with maternal 
antibodies (lower levels than in Paper IV, as measured with the same ELISA), has 
been investigated by challenge three weeks after vaccination (Mawhinney et al., 
2005). A significant reduction of viral shedding was observed in calves 
immunised with the inactivated but not with the live vaccine. However, the 
clinical disease did not differ from controls (mild BRD). An experimental 
inactivated BRSV vaccine (Intervet UK Ltd), based on persistently BRSV infected 
bovine cells and administered at two and six weeks of age, also induced partial 
protection against virus shedding (as determined by virus isolation) after a 
challenge that induced mild BRD. When boostered again at 18 weeks of age, 
however, no virus was isolated after challenge at 43 weeks of age and clinical 
signs were significantly decreased (respiratory rates of 51-70 min
-1 and dyspnea, 
but no fever, was reported in controls) (Patel & Didlick, 2004). This indicated a 
protective and rather durable response. 
 
Practical implications for the commercial inactivated vaccine 
Probably the CV investigated in this thesis induces partial protection against virus 
shedding and clinical signs in seronegative calves (at least shortly after 
vaccination). The effect in calves with maternal antibodies at vaccination is 
questionable, but since the vaccine is intended for use in calves from two weeks of 
age, controlled field studies should be performed to further evaluate its efficacy in 
this animal group. The challenge in Paper IV might be more severe than during 
natural infections, however, the challenge in some other published experimental 
trials is probably milder.  
 
Practical implications for the experimental BRSV-ISCOMs 
As an efficient inactivated subunit vaccine, the BRSV-ISCOMs would be of great 
use in Sweden and worldwide. The strong virological protection opens up 
possibilities not only to fully prevent clinical disease, but also to stop virus 
circulation within and between herds. For BRSV, this is probably unique. 
However, before coming forward as a candidate for large-scale production, further  
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evaluation needs to be done on younger calves, the duration of immunity and the 
safety of this vaccine. The results will be important for HRSV vaccine research. In 
addition, it is possible to use the ISCOMs as an experimental tool to find 
immunological markers involved in the protection against BRSV. This will affect 
the understanding of other viral infections in cattle. 
 
Implications for future research 
In parallel with an improved communication on calf management with our ‘new’, 
expanding farmers and their employees, I believe that it is important to further 
investigate the epidemiological patterns of BRSV, PIV-3 and BCoV. To prevent 
these infections without effective vaccines, we need to understand whether they 
are constantly introduced from outside the herds or whether they are able to 
remain in herds. Investigations on outbreaks where many or all animals are 
followed up serologically during several years after virus introduction are valuable 
and should be repeated in herds with different production systems. Such 
investigations in Swedish herds have previously indicated self-clearance of BRSV 
and BCoV (Alenius et al., 1991; Elvander, 1996).  
 
Virus sequencing data on repeated infections in the same herd should be obtained 
to elucidate whether new strains are introduced (even though sequence variation 
may be explained by virus evolution in latently infected animals). In such herds, it 
is interesting to repeatedly sample a selection of animals for virus detection to 
understand which age groups of animals are the main viral shedders and how long 
the virus can circulate in the herd. The fRT-PCR evaluated in this thesis could be 
used for this purpose since many samples may be analysed at low costs. These 
data would be precious so that practical advice could be given on how long herds 
should be kept under restrictions after the debut of disease, e.g. for sale of animals 
to other herds. 
 
Moreover, sentinel animals could be used to understand how long the viruses can 
survive in the environment, in a similar manner that has been done for BVDV 
(Niskanen & Lindberg, 2003). Studies on HRSV have shown survival of this virus 
in the environment for about six hours, in quantities large enough for isolation in 
vitro (Hall, Douglas & Geiman, 1980). No such studies have been done for BRSV, 
but it can be assumed that the two viruses have a similar susceptibility. Perhaps the 
survival of BRSV will be shown to be much longer (days, weeks) if sentinel 
animals are used for its detection (e.g. detection of infections in sentinels by 
serology). To investigate indirect spread by man, different standardized cleaning 
procedures can be performed after visiting a donor herd with a BRSV or BCoV 
outbreak and before visiting sentinel animals in isolation facilities. Sweden is a 
suitable country to carry out such studies because several other infections are 
absent and infections can be studied with less risk of viral co-infections.  
 
Because of the complex etiology of enzootic pneumonia, a simultaneous detection 
of several viruses and bacteria is desirable. Real-time PCR assays should be  
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designed and the protocols standardised so that several pathogens may be targed in 
a single PCR run. This will facilitate the diagnosis. 
 
Other areas to which efforts should be concentrated are BRD vaccine 
development, as well as evaluation of treatments with non-steroid anti-
inflammatory drugs (NSAIDs) and steroids. Commercially available vaccines, 
NSAIDs and steroids should be objectively evaluated in controlled field studies, in 
which the evaluators are blinded as to treatment group, animals are randomized to 
treatments and disease criteria are clearly defined. The BRSV-ISCOMs evaluated 
in this thesis should also be tested in the field after additional experimental studies 
on safety and duration of protection. 
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Concluding remarks 
•  BRSV, PIV-3 and BCoV were common infections in investigated 
Swedish beef and dairy cattle and were likely circulating throughout the 
year.  
 
•  Serological data in herds were homologous, indicating efficient spread of 
viruses within herds. This allowed retrospective investigations on virus 
presence in herds by sampling of a small number of animals.  
 
•  The geographical distribution of infected herds indicated transmission of 
virus between herds; moreover, infections in dairy herds that were closed 
with regard to animal introduction indicated possible indirect 
transmission of virus. 
 
•  A bull testing station was kept BVDV-free during six years, by testing 
animals before admission. Freedom of BVDV and BHV-1 probably 
reduced treatment rates after commingling of animals from a large 
number of herds. Differences in treatment rates were observed for 
different breeds. 
 
•  BRSV was involved in an outbreak of respiratory disease at the bull 
testing station, supporting earlier data on the clinical importance of this 
virus. Also, in the dairy herds, absence of BRSV, PIV-3, BCoV and 
BVDV was significantly correlated to absence of disease, enforcing the 
benefit of limiting these infections. 
 
•  A fluorogenic RT-PCR to detect BRSV had high relative sensitivity and 
high analytic specificity. The assay was more rapid and allowed higher 
sample throughput than classical gel-based nested PCR, showing its 
suitability for BRSV research as well as for diagnostic purposes. 
 
•  A Danish BRSV infection model was confirmed to be reproducible. 
Severe clinical signs of BRD were reproduced in conventional colostrum-
fed calves with maternal antibodies to BRSV. 
 
•  In contrast to a commercial inactivated vaccine, an experimental BRSV-
ISCOM vaccine induced rapid humoral immune responses and strong 
clinical and virological protection against experimental BRSV challenge 
despite maternal antibodies in calves at vaccination. The BRSV-ISCOMs 
are not only candidates for future industrial production after further 
evaluation, they may also serve as tools to elucidate protective 
immunological parameters against BRSV. 
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